文献速递关节外科骨质疏松与代谢性骨病

二甲双胍使用与膝髋骨关节炎发病率、进展及关节置换风险的关联:系统综述与Meta分析

Association of Metformin Use With Osteoarthritis Incidence, Progression, and Joint Arthroplasty Risk in the Knee and Hip: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Arthroplasty · 2025-10-09

该系统综述与Meta分析纳入13项研究共167,107例,评估二甲双胍对膝髋骨关节炎发病率、影像学/症状进展及关节置换风险的影响。结果显示二甲双胍使用者骨关节炎发病率降低33%(RR 0.67,95%CI 0.61-0.74),关节置换风险降低43%(RR 0.57,95%CI 0.38-0.84)。作者认为二甲双胍可能降低骨关节炎发病率并延缓进展,但需试验确认其在无明确骨关节炎的糖尿病/肥胖患者中的疗效。

要点

  • 二甲双胍使用者膝髋骨关节炎发病率降低33%(RR 0.67,95%CI 0.61-0.74)。
  • 二甲双胍与关节置换风险降低43%相关(RR 0.57,95%CI 0.38-0.84)。
  • 已有骨关节炎者(RR 0.37)及治疗超过2年者(RR 0.38)保护更明显。

核心结论

  • 二甲双胍可能降低膝髋骨关节炎发病率并延缓影像学/症状进展。
  • 二甲双胍显著降低关节置换风险,尤其在已有骨关节炎和接受长期治疗的患者中。
  • 作者认为这些发现支持在已有骨关节炎的亚组中考虑使用二甲双胍,同时强调需试验确认其在无明确骨关节炎的糖尿病/肥胖患者中的疗效。

研究设计与样本

  • 系统综述与Meta分析,遵循PRISMA指南,检索PubMed、Web of Science、Embase和Cochrane Library数据库。
  • 纳入13项研究,共167,107例病例,对预设结局进行随机效应Meta分析和定性综合。

主要发现

  • 二甲双胍使用者膝髋骨关节炎发病率降低33%(汇总RR 0.67,95%CI 0.61-0.74)。
  • 定性综合显示二甲双胍使用者磁共振成像评估的内侧软骨损失减少,疼痛、关节功能和生活质量的症状进展延迟。
  • 二甲双胍与关节置换风险降低43%相关(汇总RR 0.57,95%CI 0.38-0.84)。
  • 已有骨关节炎者相比仅有糖尿病/肥胖者保护更强(RR 0.37 vs 0.81)。
  • 治疗超过2年者相比2年或以下者保护更强(RR 0.38 vs 0.80)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需试验确认二甲双胍在无明确骨关节炎的糖尿病/肥胖患者中的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although hip and knee osteoarthritis (OA) constitutes a major cause of disability globally, disease-modifying therapies do not exist. Preclinical evidence suggests that metformin has disease-modifying potential, but clinical evidence is conflicting. This meta-analysis assessed the effect of metformin on 1) hip/knee OA incidence, 2) radiographic/symptomatic progression, and 3) joint arthroplasty (JA) risk. METHODS: We systematically searched the PubMed, Web of Science, Embase, and Cochrane Library databases, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Random-effects meta-analyses and qualitative synthesis were performed for the prespecified outcomes. RESULTS: Evidence from 13 studies enrolling 167,107 cases demonstrated that metformin users had a 33% lower hip/knee OA incidence (pooled risk ratios (RRs) 0.67, 95% confidence intervals (CI) 0.61 to 0.74). Qualitative synthesis indicated reduced magnetic resonance imaging-assessed medial cartilage loss and delayed symptomatic progression with respect to pain, joint function, and quality of life among metformin users. Crucially, metformin was associated with a 43% lower joint arthroplasty risk (pooled risk ratio (RR) 0.57, 95% confidence interval (CI): 0.38 to 0.84), with enhanced protection in those who had pre-existing OA versus those who had diabetes/obesity alone (RR 0.37 versus 0.81) and those receiving more than two years versus two years or less of treatment (RR 0.38 versus 0.80). CONCLUSIONS: Metformin may reduce hip/knee OA incidence and slow radiographic/symptomatic progression. It significantly reduces the risk of joint arthroplasty, particularly in patients who have pre-existing OA and receive prolonged metformin therapy. These findings support considering metformin in this subgroup while highlighting the need for trials to confirm its efficacy among patients who have diabetes/obesity, but do not have established OA.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Yao K, Yue C, Li Y, et al. Association of Metformin Use With Osteoarthritis Incidence, Progression, and Joint Arthroplasty Risk in the Knee and Hip: A Systematic Review and Meta-Analysis. J Arthroplasty. 2025. PMID: 41067453. doi:10.1016/j.arth.2025.09.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。